The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AcelRx Pharmaceuticals been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AcelRx Pharmaceuticals is a member of our Medical group, which includes 838 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ACRX is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ACRX's full-year earnings has moved 5.12% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ACRX has moved about 8.66% on a year-to-date basis. At the same time, Medical stocks have gained an average of 5.03%. As we can see, AcelRx Pharmaceuticals is performing better than its sector in the calendar year.
Breaking things down more, ACRX is a member of the Medical - Drugs industry, which includes 177 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has gained an average of 11.46% so far this year, meaning that ACRX is slightly underperforming its industry in terms of year-to-date returns.
ACRX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AcelRx Pharmaceuticals been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
AcelRx Pharmaceuticals is a member of our Medical group, which includes 838 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ACRX is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for ACRX's full-year earnings has moved 5.12% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ACRX has moved about 8.66% on a year-to-date basis. At the same time, Medical stocks have gained an average of 5.03%. As we can see, AcelRx Pharmaceuticals is performing better than its sector in the calendar year.
Breaking things down more, ACRX is a member of the Medical - Drugs industry, which includes 177 individual companies and currently sits at #74 in the Zacks Industry Rank. On average, this group has gained an average of 11.46% so far this year, meaning that ACRX is slightly underperforming its industry in terms of year-to-date returns.
ACRX will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>